Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1689 studies found for:    rituximab
Show Display Options
Rank Status Study
1 Withdrawn Rituximab for GVHD
Conditions: Graft vs Host Disease;   Alogenic Hematopoietic Transplant
Intervention: Drug: Rituximab
2 Completed Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab
Conditions: Renal Transplant;   Autoimmune Diseases
Interventions: Drug: Rituximab 375;   Drug: rituximab 1000
3 Terminated
Has Results
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
Conditions: Leukemia;   Acute Lymphoblastic Leukemia;   ALL
Intervention: Drug: rituximab
4 Active, not recruiting Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus
Condition: Pemphigus Disease
Interventions: Drug: General Corticotherapy;   Drug: Rituximab
5 Terminated Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation
Conditions: Grafting;   Renal Transplantation;   Transplantation, Kidney;   Chronic Allograft Nephropathy
Intervention: Drug: MabThera
6 Completed
Has Results
Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
Conditions: Anemia, Aplastic;   Red-Cell Aplasia, Pure;   Anemia, Diamond-Blackfan
Intervention: Drug: Rituximab
7 Completed Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid
Condition: Bullous Pemphigoid
Intervention: Drug: Mabthera
8 Recruiting Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy
Condition: Prostate Cancer
Intervention: Drug: rituximab
9 Completed
Has Results
Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT
Conditions: Hodgkin's Disease;   Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
Intervention: Drug: Rituximab
10 Terminated A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)
Condition: Graft Versus Host Disease
Intervention: Drug: Rituximab
11 Completed Rituximab to Treat Stiff Person Syndrome
Condition: Stiff Person Syndrome
Interventions: Drug: Rituximab;   Drug: rituximab or placebo
12 Active, not recruiting Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
Conditions: Leukemia;   Lymphoid Malignancies;   Metastatic Malignant Neoplasm to the Leptomeninges
Intervention: Drug: Intrathecal Rituximab
13 Recruiting A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Condition: Granulomatosis With Polyangiitis
Intervention: Drug: Rituximab
14 Completed Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
Condition: Multiple Sclerosis
Intervention: Drug: Rapid Infusion Rituximab
15 Completed Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP
Condition: Immune Thrombocytopenic Purpura
Intervention: Drug: Rituximab and dexamethasone
16 Recruiting Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders
Conditions: Hematologic Disorders;   Oncologic Disorders;   Rheumatologic Disorders
Intervention: Drug: Rituximab
17 Withdrawn Alemtuzumab and Rituximab in Aplastic Anemia
Condition: Aplastic Anemia
Intervention: Drug: Alemtuzumab and Rituximab
18 Active, not recruiting Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
Condition: Fibrillary Glomerulonephritis
Intervention: Drug: rituximab
19 Completed Safety and Tolerability of Rituximab in Neuromyelitis Optica
Condition: Neuromyelitis Optica
Intervention: Drug: Rituximab
20 Active, not recruiting To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan
Condition: Lymphoma, Follicular
Interventions: Biological: rituximab;   Biological: CT-P10

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.